

Commonwealth of Massachusetts

MassHealth Drug Utilization Review Program

P.O. Box 2586

Worcester, MA 01613-2586

First name

Fax: 1-877-208-7428 **Phone:** 1-800-745-7318

Trofile Assay and Selzentry (maraviroc) Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

MassHealth member ID no.

Date of birth | Sex (Circle one.)

f m

PA is required for all Selzentry (maraviroc) and Trofile Assay requests.

Information about the MassHealth Drug List can be found at www.mass.gov/druglist.

MI

Member information

Last name

Member's place of residence ☐ h	ome nursing facility					
Medication information						
□ trofile assay	Selzentry (maraviroc) (evidence of a positive assay is required for approval) Dose, frequency, and duration					
Indication						
☐ HIV-1 ☐ Other (specify):_						
Current viral load						
Section I						
1. Does your patient have treatment failure one agent from three of the four antiretr	documented by an HIV-1 RNA > 5,000 copies/ml despite at least 6 months of prior therapy with at least oviral categories listed below?					
□ ≥1 nucleoside reverse transcriptase inhibitors (NRTI)						
□ ≥1 non-nucleoside reverse transcriptase inhibitors (NNRTI)						
□ ≥2 protease inhibitors (PI)						
☐ enfuvirtide (fusio	enfuvirtide (fusion inhibitor)					
yes if no, - Please provide documentati	ion of medical necessity or rationale for requested assay or medication.					

PA-22 (12/07) over ▶

Section II							
Treatment Plan							
1. If requesting maraviroc, p	olease provide results of trof	île assay indicating positive CCF	R5-tropic HIV-1 infection.				
2. If requesting maraviroc, v	vill concurrent antiretroviral	therapy be prescribed?					
	vide treatment regimen belo						
	□ No. Please provide rationale why combination therapy is not indicated below.						
Pharmacy inform	lation	Pharmacy provider no.	Telephone no.	Fax no.			
		Optional	()	()	Optional		
Address			City	State	Zip Optional		
Prescriber inforn							
Last name	First name	MI	MassHealth provider no.	DEA no.			
Address			City	State	Zip		
E-mail address			Telephone no.	Fax no.			
		Optional	()	/ /			
Signature							
		nplete to the best of my know	ledge, and I understand that	any falsification, d	omission, or		
concealment of material fact	may subject me to civil or cr	iminal liability.					
Prescriber's signature (Stamp not accepted.) Date							